Telix Pharmaceuticals (NASDAQ:TLX) Trading Down 4.3% - Should You Sell?

Key Points

• Telix Pharmaceuticals shares fell 4.3% to about $11.81 in Friday’s midday trading, with volume down 90% versus the stock’s average daily volume.
• Analyst sentiment remains broadly positive but mixed: Telix has a consensus “Moderate Buy” rating and a $20.40 price target, though RBC downgraded the stock to “sector perform” and Weiss Ratings maintained a sell rating.
• Several institutional investors—including Russell Investments, Jane Street and JPMorgan—recently initiated or increased positions, while Telix continues developing targeted radiopharmaceuticals for cancer diagnosis and treatment.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s share price dropped 4.3% during mid-day trading on Friday . The company traded as low as $11.75 and last traded at $11.8050. 19,705 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 197,524 shares. The stock had previously closed at $12.33.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TLX. Citigroup decreased their price target on Telix Pharmaceuticals from $22.50 to $22.00 and set a "buy" rating on the stock in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Friday, July 17th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Friday, July 17th. Finally, Wedbush reissued an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.40.

Telix Pharmaceuticals Stock Down 4.1%

The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The business's 50-day simple moving average is $10.67 and its 200-day simple moving average is $9.49.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $975,000. Jane Street Group LLC acquired a new position in shares of Telix Pharmaceuticals in the second quarter worth $564,000. IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $213,000. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock valued at $25,000 after acquiring an additional 1,392 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Telix Pharmaceuticals during the third quarter valued at $243,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source